Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.